In the described studies, genetic constructs effectively reduced heparanase enzyme expression, resulting in reduced tumor invasiveness and suppression of angiogenesis and metastasis, but approaches based on genetic suppression of heparanase have not been widely used in clinical trials [103,104,105]. This evidence concerns the gene HPSE and neoplasm.